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Background: Endothelial cells (ECs) are responsible for creating a tumor vascular niche as well as producing
angiocrine factors. ECs demonstrate functional and phenotypic heterogeneity when located under different
microenvironments. Here, we describe a tumor-stimulated mesenchymal phenotype in ECs and investigate its
impact on tumor growth, stemness, and invasiveness.
Methods: Xenograft tumor assay in NOD/SCID mice and confocal imaging were conducted to show the acquisition of
mesenchymal phenotype in tumor-associated ECs in vivo. Immunocytochemistry, qPCR and flow cytometry techniques
showed the appearance of mesenchymal traits in ECs after contact with breast tumor cell lines MDA-MB231 or MCF-7.
Cell proliferation, cell migration, and sphere formation assays were applied to display the functional advantages of
mesenchymal ECs in tumor growth, invasiveness, and enrichment of tumor initiating cells. qPCR and western blotting
were used to investigate the mechanisms underlying EC mesenchymal transition.
Results: Our results showed that co-injection of ECs and tumor cells in NOD/SCID mice significantly enhanced tumor
growth in vivo with tumor-associated ECs expressing mesenchymal markers while maintaining their intrinsic endothelial
trait. We also showed that a mesenchymal phenotype is possibly detectable in human neoplastic breast biopsies as
well as ECs pre-exposed to tumor cells (ECsMes) in vitro. The ECsMes acquired prolonged survival, increased migratory
behavior and enhanced angiogenic properties. In return, ECsMes were capable of enhancing tumor survival and
invasiveness. The mesenchymal phenotypes in ECsMes were the result of a contact-dependent transient phenomenon
and reversed upon removal of the neoplastic contexture. We showed a synergistic role for TGFβ and notch pathways
in this phenotypic change, as simultaneous inhibition of notch and TGFβ down-regulated Smad1/5 phosphorylation
and Jag1KD tumor cells were unable to initiate the process.
Conclusions: Overall, our data proposed a crosstalk mechanism between tumor and microenvironment where
tumor-stimulated mesenchymal modulation of ECs enhanced the constitution of a transient mesenchymal/
endothelial niche leading to significant increase in tumor proliferation, stemness, and invasiveness. The possible
involvement of notch and TGFβ pathways in the initiation of mesenchymal phenotype may propose new
stromal targets.
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Endothelial cells (ECs) are the building blocks of the
vascular system and are characterized as the single-cell
layer of epithelium that forms the inner cell lining of
blood vessels and lymphatics [1]. Vascular ECs were ini-
tially considered passive conduits for delivering oxygen
and nutrients to all tissues [2,3]. The development of
appropriate culturing systems for primary human organ-
specific ECs provided the opportunity to identify EC het-
erogeneity in different organs as well as their functional
properties under normal and pathological conditions [4-6].
Today, ECs have been implicated in several perfusion-
independent processes including tissue regeneration, tumor
growth and dormancy through secretion of angiocrine fac-
tors [7-14]. In addition, increasing evidence reveals that
endothelial cellular identity is more plastic than previously
thought [15]. This plasticity results in phenotypical and
functional modifications under different contextual condi-
tions. A characteristic example of such phenotypic modifi-
cation is endothelial-to-mesenchymal transition (EndMT),
during which ECs lose their endothelial phenotype and ac-
quire mesenchymal traits [16-18]. EndMT is implicated in
tumor progression through complex modulation of the
tumor and its stroma [17]. It is likely that precise analysis
of cellular transformation in tumor microenvironments will
reveal subsets of additional cellular phenotypes that might
be drug targets and/or biomarkers.
In this study, we aimed to investigate the role of tumor
cells in promoting mesenchymal phenotype in ECs by
setting up tumor-endothelial co-culture systems in the
absence of serum or cytokine supplementations. We ini-
tially confirmed the induction of mesenchymal phenotype
in Human Umbilical Vein Endothelial Cells (HUVECs) by
breast tumor cells. Then, to overcome the barrier of endo-
thelial sensitivity to starvation and tumor cell-induced cell
death [19], we continued our work with the previously de-
scribed E4-ECs (that we here refer to as ECs) [10,20-22].
ECs were produced through transfection of Primary Endo-
thelial Cells (PECs) with adenoviral E4ORF1 gene as de-
scribed previously [21]. While this transfection provides a
low Akt activation allowing endothelial survival in a serum
and cytokine-free condition, it does not modify the endo-
thelial phenotype as has been widely used [10,20,22]. Be-
sides, activation of Akt in tumor endothelium has been
previously reported [23] and our model might thus be
more optimal to mimic the crosstalk between ECs and
cancer cells in vivo without any background effect. Using
breast cancer cells (BCCs), we showed that BCCs in co-
culture with ECs stimulated transcriptomics modification
of ECs partly represented by acquisition of mesenchymal
phenotype. While a similar phenomenon (EndMT) has
already been described in the developmental and patho-
logical context, we were able to show that tumor cells
were capable of stimulating mesenchymal phenotypes inECs and the tumor-associated ECs retained their endothe-
lial properties while gaining mesenchymal phenotypes. In
addition, this transition was reversible and dependent on
continuous contact between ECs and BCCs. Subsequently,
we showed that the mesenchymal ECs were capable of
constituting a pro-tumoral niche responsible for increas-
ing BCC proliferation, mammary stem cell self-renewal,
and pro-metastatic properties. Our results also suggest
that tumor-promoted mesenchymal shift in ECs is regu-
lated by Smad signaling through the synergistic stimula-
tion of TGFβ and notch pathways.
Methods
Cell culture & reagents
Breast cancer cell lines MDA-MB231 (MDA-231), MCF-7,
and HUVEC were purchased from American Type Culture
Collection (ATCC, USA). GFP+ECs (ECs) were developed
as described previously [21]. Human recombinant Jagged1
and TGFβ1 were obtained from R&D Systems and
PeproTech, respectively. Υ-secretase inhibitors (GSI)
and SB-431542 were purchased from Sigma (USA).
Breast cancer cells (BCCs) were grown in DMEM/
High glucose (HyClone, USA) supplemented with 10%
FBS, L-glutamine, non-essential amino acids (NEAA),
and penicillin/streptomycin in a humidified incubator
with 5% CO2. ECs were grown in M199 growth medium
(Gibco, USA) supplemented with 20% FBS, 20 ng/ml
β-Endothelial Cell Growth Factor (βECG), 20 units/ml
heparin and penicillin/streptomycin. The co-cultures
were prepared by mixing one part BCCs with 10 parts
GFP+ECs (1:10 ratio) and cells were grown in 1:1 ratio of
DMEM/High and M199 media in the absence of serum
and growth factors (complete starvation). Co-cultivation
of BCCs and ECs was performed over 3–5 days under ad-
herent condition.
Sphere forming assay
Sphere forming assay was used to enrich mammary stem
cells (mammospheres) as previously described by Dontu
[24]. We slightly modified that protocol and co-cultured
mammospheres with GFP+ECs at 1:10 ratio under non-
adherent condition to obtain mammo-angiospheres.
Mammo-angiospheres were therefore composed of both
tumor and GFP+ endothelial colonies mingling together.
Spheres were grown in a so-called “3D media” as de-
scribed by Dontu and colleagues by using DMEM-F12
(HyClone, USA) supplemented with 2% B27, 20 ng/mL
basic fibroblast growth factor (bFGF) and epidermal
growth factor (EGF), and 5 μg/mL insulin. In order to
prevent the formation of cellular aggregates, a highly
viscose 3D media was prepared by addition of 0.2%
methylcellulose (Sigma, USA). Stem cell enrichment was
evaluated by measuring the perimeter of mammospheres
or angiospheres with NIH ImageJ 64 software or by
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used to distinguish angiospheres.
Cell proliferation assay
MDA-231 or MCF-7 cells were co-cultured with GFP
+ECs (1:10 ratio) under starvation and ECs survival was
assessed at different intervals by trypsinization and re-
peated manual counting by hemacytometer. A GFP filter
was used to distinguish the GFP+ECs from unstained
BCCs. In this study, ECs that have been pre-exposed to
BCCs are referred to as ECsMes, whereas ECsNorm are
normal ECs with no prior contact with BCCs. To see the
effect of ECsMes on BCC proliferation and survival, GFP
+ECs were directly co-cultured with MDA-231 and
MCF-7 cells for three to five days to obtain GFP+ECsMes
prior to initiating a proliferation assay. Next, we started
a proliferation assay with ECsMes while still growing with
BCCs and newly established co-cultures of GFP+ECsNorm
and BCCs for seven more days under complete starvation.
BCCs either in mixture with GFP+ECsNorm or GFP+ECsMes
were then counted by trypsinization and manual counting
excluding ECs by GFP filter.
Flow cytometry & cell sorting
Antibodies to human PE-CD31 (560983), AF647-VE-
cadherin (561567), and fibronectin (FN1, 610077) were
purchased from BD Biosciences (USA). AF633-F-actin
(phalloidin, 22284) is a product of Invitrogen (USA),
vimentin (5741) and α-SMA (ab5694) are from Cell Sig-
naling Technologies and Abcam, respectively (USA). The
secondary antibodies were purchased from Invitrogen.
GFP+ECs were either cultured alone or co-cultured with
BCCs. To stain ECs in mono or co-cultures, cells were
initially trypsinized and washed with PBS. For labeling
intracellular proteins, cells were initially fixed then perme-
abilized on ice in freshly prepared 3.7% paraformaldehyde
and 0.1% TritonX-100 for 10 minutes/each prior to incu-
bation with primary antibodies (permeabilization by
TritonX-100 was not carried out for cell surface proteins).
Briefly, cells were resuspended at 1 × 106 cells/100 μL
density in a staining buffer containing 5% FBS, 1% BSA,
0.2 mM EDTA in PBS. To enhance the specificity of stain-
ing, FcR blocking (Miltenyi Biotec, USA) was added at
5 μL/1 × 106 cells prior to incubation with primary anti-
bodies. Primary antibodies were then added according to
the instructions provided by the manufacturers and incu-
bation was done for 1 hour at 4°C. After washing, cells
were stained with secondary antibodies for 30 minutes at
4°C followed by washing. Fluorescent light (FL) was quan-
tified using Fluorescence Activated Cell Sorting (FACS)
on a SORP FACSAria II (BD Biosciences), eGFP fluores-
cence was acquired using a 488 nm blue laser and 510/
50 nm emission, Phycoerythrin fluorescence (PE) was ac-
quired using a 498 nm blue laser and 575/26 nm emission.Alexa Fluor® 647 fluorescence was obtained with a 650 nm
red laser and 660/20 nm emission, while Alexa Fluor® 633
was obtained with 633 nm red laser and 647 nm emission.
The figures display the median of fluorescence intensity
(MFI) relative to controls. Doublets were excluded by
FSC-W × FSC-H and SSC-W × SSC-H analysis, and single
stained channels were used to compensate. Fluorescent
minus one was used for gating. 10,000-30,000 events were
acquired per sample. Finally, data were processed with
FACSDiva 6.3 software (BD Biosciences) or Summit 4.3
(Dako).
For sorting GFP+ECs, GFP fluorescence was acquired
using 488 nm blue laser and 510/50 nm emission and
sorting was done using purity masks [13]. For sorting
BCCs, cancer cells were stained with a PE-conjugated
dye called PKH26 (Sigma, USA) prior to co-culture and
PE fluorescent was acquired using 496/566 nm blue laser
and 576 nm emission to separate them from GFP+ECs.
Control GFP+ECs or PKH+BCCs monocultures were
processed and sorted to normalize the cellular stress
caused by cell sorting.
Wound healing assay
GFP+ECs and PKH26+BCCs were co-cultured under
starvation for 3–5 days, and then the cells were sorted
as described in the previous section. Sorted ECs or can-
cer cells were immediately plated and grown at 100%
confluence in complete medium to recover overnight.
Next, they were continued to culture under complete
starvation for 6 hours to impede cellular growth before a
wound healing assay was initiated [25]. Finally, the mi-
gration capability of cells to close the wound (scratch)
was evaluated after 48 hours using NIH ImageJ 64
software.
Tube forming assay
Growth factor reduced Matrigel (BD Biosciences, USA)
was thawed at 4°C overnight, and added to each well of
a 48-well plate (120 μL/well) and allowed to solidify for
30 minutes at 37°C. GFP+ECs were sorted from BCCs
and immediately plated on matrigel at subconfluent
density (2.5 × 104 cells/well). The formation of capillary-
like structures was examined with an inverted microscope
after 24 hours and the number of capillary junctions was
quantified by analyzing the digitized images.
Immunocytochemistry
Antibodies against PE-CD31 (560983), AF647-VE-Cadherin
(561567), and FN1 (610077), CD44 (555478) and desmin
(550626) were purchased from BD Biosciences. F–actin
(AF633-phalloidin, 22284) is a product of Invitrogen,
whereas vimentin (5741) and α-SMA (ab5694) antibodies
are products of Cell Signaling Technologies and Abcam, re-
spectively. Anti-fade gold DAPI and secondary antibodies
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and imaged on glass chamber slides (Lab-Tek®). Briefly, the
adherent cells were washed once with PBS and fixed in
3.7% formaldehyde, then permeabilized in 0.1% Triton X-
100 for 20 minutes (no permeabilization required for cell
surface proteins). After one wash, the cells were blocked for
30 minutes in a buffer containing 3% FBS and 1% BSA for
one hour. Primary antibodies were prepared according to
the instruction provided by the manufacturers and incuba-
tion was done for two to three hours on a shaker at normal
temperature. After washing, the cells were incubated with
secondary antibodies for 30 minutes. The fluorescent sig-
nals were acquired on a Zeiss Confocal Laser Scanning
Microscope 710 (Carl Zeiss).
Immunohistochemistry
All antibodies are listed in the previous section.
Formalin-fixed paraffin-embedded (FFPE) sections of
neoplastic human breast biopsies were deparaffinized by
dipping the slides in xylene for 15 minutes. The sections
were rehydrated by immersing them in serial dilution of
ethanol for 5 minutes followed by rinsing. Antigen re-
trieval was performed by boiling the slides in citrate
buffer (pH 6.0) for 15 minutes. Snap frozen sections of
human xenograft tumors were thawed briefly, fixed and
permeabilized as described above. Primary antibody in-
cubation was carried out overnight at 4°C in a moisture
chamber after a 30-minute blocking period. Secondary
antibodies were incubated for one hour followed by sev-
eral washes. Slides were then mounted with DAPI.
shRNA transfection
Human shJagged1, scrambled lentiviral particles, and
polybrene were purchased from Santa Cruz Biotechnol-
ogy (USA). In summary, cells were cultured up to 50%
confluence and were then treated with polybrene and
lentiviral particles containing shRNA against Jagged1 or
scrambled particles. Transfected cells were then selected
using puromycin, and the down-regulation of Jagged1
was assessed by qPCR.
RNA extraction & qPCR analysis
Total RNA was extracted with RNeasy Mini Kit (250)
from Qiagen according to the manufacturer’s instruc-
tions. The RNA concentration was measured with Nano-
drop 8000 spectrophotometer (Thermo Scientific) and
1 μg of RNA was used to produce cDNA with the Proto-
Script M-MuLV Taq RT-PCR kit using the oligo dT
primers (New England BioLabs). Semi-quantitative real-
time analysis (qPCR) was done with a 7500 qPCR Sys-
tem (Applied Biosystems, USA) using a GoTaq 2-step
RT-qPCR System (Promega) to amplify the gene of
interest following the instructions provided. Primer se-
quences are listed in Additional file 1: Table S1.Protein extraction & western blot analysis
Cells were lysed in RIPA buffer (Sigma) containing pro-
tease and phosphatase inhibitors. For each sample, 40 μg
of total protein were analyzed by Western blot. Proteins
were separated on 10% SDS polyacrylamide gels and elec-
troblotted at 4°C onto polyvinylidene difluoride (PVDF)
membranes for one hour. The membranes were blocked
in 5% nonfat dry milk or bovine serum albumin (BSA) in
0.1% Tween 20 in Tris-buffered saline prior to incuba-
tion with primary antibodies at 4°C overnight. The
antibodies included phospho-Smad5 (1:500, Abcam,
ab76296), phospho-Smad3 (1:500, Bioss, bs-3425R),
Smad5 (1:1000, Cell Signaling, 9517), Smad3 (1:1000,
Cell Signaling, 9523), Hes1 (1:200, Millipore), and β-actin
(1:3000, Sigma, A2228). Blots were developed using HRP
and chemiluminescence peroxidase substrate (Immuno-
Cruz) (Santa Cruz Biotechnology) and FluroChem HD2
(Cell Biosciences).
RNA extraction & microarray analysis
RNA was isolated as explained above. Two quality con-
trol measures were carried out: (1) a spectrophotometric
analysis and (2) a size fractionation procedure using a
microfluidics instrument (Agilent Technologies). Total
RNA (200 ng) was analyzed on Affymetrix GeneChip
Human Genome U133 Plus 2.0 Array. Data were ana-
lyzed using Partek Software (V6.09.1110-6; Affimetrix),
Venny online software (BioinfoGP; CNB-CSIC) and In-
genuity Pathway analysis (Ingenuity Systems, Redwood
City, CA). Class comparisons between ECsNorm and ECsMes
(three biological replicates of each) were performed to iden-
tify gene expression changes with significant expression
differences (p < 0.05) and two-fold increase or decrease in
expression.
Human xenograft tumor formation in NOD/SCID mice
All animal procedures were approved by the Ethics
Committee for animal experimentation of Weill Cornell
University (New York, USA). Six-week old female NOD/
SCID mice were purchased from Jackson Laboratories.
MDA-231 cells were injected (2 × 105) with or without
2 × 106 ECs (1:10 ratio) in the mice mammary fat pad of
NOD/SCID mice. Four mice were assayed for each
group. Each mouse received an injection of tumor cells
on the left and co-injection of tumor and endothelial
cells on the right side. The mice were euthanized and
checked for tumor formation 18 and 30 days after inocu-
lation. The extracted tumors were snap frozen for histo-
logical analysis.
Ingenuity pathway analysis
We used Ingenuity Pathway Analysis software (IPA)
(Ingenuity Systems, Redwood City, CA) for network ana-
lysis of EC genes that were differentially regulated upon
Figure 1 (See legend on next page.)
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Figure 1 Tumor-associated ECs enhance human xenograft tumor formation and demonstrate a mesenchymal phenotype in breast
tumors. A) NOD/SCID mice were sacrificed 18 and 30 days after subcutaneous injection with MDA-231 cells (2 × 105 cells) with or without ECs
(2 × 106 cells) to make an assessment on xenograft tumor burden. Injection of MDA-231 cells without ECs (shown on the right side of each image)
resulted in formation of non-angiogenic small tumors. In contrast, inoculation of MDA-231 cells mixed with ECs (1:10 ratio) (shown on the left
side of each image) led to the generation of bulkier angiogenic tumors. B) Quantification of xenograft tumor weights formed in NOD/SCID
mice injected by MDA-231 cells with and without ECs (***p < 0.001). C) Snap-frozen angiogenic xenograft tumors sections were stained with
endothelial marker CD31 as well as vascular structural and functional markers CD44 and desmin to show the existence of viable capillaries in
xenograft tumors. D) The xenograft tumor sections were stained with mesenchymal markers vimentin and α-SMA to demonstrate the acquisition
of mesenchymal phenotype by tumor vasculature. E) Human neoplastic breast tissues were examined for the potential occurrence of mesenchymal
properties in tumor endothelium in vivo. The tumor endothelium was first detected by CD31+ staining, and then examined for the existence of ECs
showing mesenchymal phenotype within tumor by vimentin and α-SMA staining. Scale bars represent 10 μm.
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IPA keywords: “Metastasis”, “Proliferation of cell lines”
and “Cell death of tumor cell line”. All edges are sup-
ported by at least one reference from the literature, text-
books, or canonical information stored in the Ingenuity
Pathways knowledge database. P-values for enrichment
of biological functions were generated based on hypergeo-
metric distribution and calculated with the right-tailed
Fisher's exact for 2 × 2 contingency tables as implemented
in Ingenuity.
Statistical analysis
All quantitative data are expressed as mean ± standard
error of the mean (SEM). Statistical analysis and graph-
ical presentation were performed using SigmaPlot 12
(Systat Software Inc., Chicago, IL) or Excel (Microsoft
Corporation). A Shapiro-Wilk normality test, with a p =
0.05 rejection value, was used to test normal distribution
of data prior to further analysis. All pairwise multiple
comparisons were performed using one-way ANOVA
followed by Holm-Sidak posthoc tests for data with nor-
mal distribution or, in case of a failed normality test, by
Kruskal-Wallis analysis of variance on ranks followed by
Tukey posthoc tests. Paired comparisons were per-
formed using Student's t-tests or Mann–Whitney rank
sum tests in case of unequal variance or failed normality
test. Statistical significance was accepted for p < 0.05 (*),
p < 0.01 (**) or p < 0.001 (***). All experiments were per-
formed in triplicate and repeated three times (n = 3).
Results
Tumor-associated ECs enhance human xenograft tumor
formation and demonstrate a mesenchymal phenotype in
breast tumors
To investigate the role of ECs in creating a pro-tumoral
niche in vivo, we injected breast tumor cells MDA-231
to the mammary fat pad of NOD/SCID mice with or
without ECs. The mice that were co-injected with
MDA-231 and ECs showed significantly higher tumor
burden with tumors weighing three-fold higher than mice
that were only inoculated with MDA-231 cells (Figure 1A
and B). Immunofluorescent imaging demonstrated thatco-injected ECs generated functional and viable vessels in
xenograft tumors (Figure 1C).
To confirm a mesenchymal phenotype in xenograft tu-
mors, tumor sections were examined for the expression
of mesenchymal markers such as vimentin and α-SMA.
We showed co-expression of mesenchymal and endothe-
lial markers in endothelium of the xenograft tumors
(Figure 1D). In order to show that the tumor-stimulated
mesenchymal properties in ECs might potentially occur
in vivo, we stained FFPE sections obtained from breast
tumor biopsies with mesenchymal markers. Similar to
xenograft tumors, breast tumor endothelium showed a
mesenchymal phenotype while maintaining an endothe-
lial trait (Figure 1E).
Breast cancer cells promote mesenchymal phenotypes in
ECs
To show that cancer cells promote a mesenchymal
phenotype in ECs, we initially used Human Umbilical
Vein Endothelial Cells (HUVECs). Our flow cytometry
results confirmed that MDA-231 cells stimulated a mes-
enchymal phenotype in HUVECs as shown by up-
regulation of mesenchymal markers (α-SMA & FSP-1)
while maintaining the endothelial trait (shown by CD31
& VE-Cadherin expression) (Additional file 1: Figure
S1). Due to oversensitivity of HUVECs to starvation and
rapid cell death, we used E4-ECs (ECs) that show rela-
tively low Akt activation and are therefore resistant to
serum-free conditions as well as tumor-cell induced
apoptosis [19,21]. We further confirmed that cancer cells
could stimulate a mesenchymal trait in ECs. The preser-
vation of vascular phenotype in the co-culture setting
was shown by stable expression of VE-cadherin and
CD31 in ECs (Figure 2A). However, we were able to de-
tect a shift toward mesenchymal phenotype represented
by increased expressions of fibronectin (FN1), vimentin
(Figure 2B, left panels), and α-SMA as well as stress fibers
(F-actin) using confocal imaging (Figure 2B, right panels).
These results were further validated by flow cytometry
analyses (Figure 2A-B). Similar findings were obtained
with ECs co-cultured with MCF-7 BCCs (Additional file 1:
Figure S2A). Therefore, the ECs exposed to BCCs that
Figure 2 (See legend on next page.)
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Figure 2 Breast cancer cells promote mesenchymal phenotypes in ECs. A) Confocal images and flow cytometry overlays showing the
maintenance of endothelial phenotype in ECs grown in contact with MDA-231 BCCs (white arrows) as shown by CD31 (right panels) and
VE-Cadherin (left panels) staining. B) Confocal images and flow cytometry overlays displaying the acquisition of mesenchymal phenotypes by ECs
co-cultured in contact with MDA-231 BCCs (white arrows). GFP+ECs grown with MDA-231 cells show the appearance of mesenchymal phenotype
by up-regulation of FN1, vimentin (left panels) α-SMA and F-actin stress fibers (right panels). Scale bars represent 10 μm. C) Semi-quantitative
qPCR analysis further validated our results by showing that ECsMes maintained their endothelial phenotypes while over-expressed mesenchymal
markers. (*** p < 0.001, **p < 0.01, *p < 0.05, mean ± SEM, n = 3). D) Heat map demonstrating differential gene expression in ECsMes (sorted from
MDA-231cells) as compared to normal ECs (left). Functions treemap (right): rectangles represent ECsMes differential functions as compared to
ECsNorm based on literature data. Functions are grouped together into large clusters such as cellular growth and proliferation, cell cycle, cell
movement etc. Rectangles are colored based on the z-score which is proportional to number of genes that are affected in any particular
functional class with orange showing activation of that function and blue representing the inhibition of that function. In our dataset of ECsMes,
some functional groups showed consistent changes among all subgroups (shaded rectangles). These groups are cellular growth and proliferation
(p-value 4.86E-29), cellular movement (p-Value 6.69E-19), cardiovascular system development (p-Value 8.30E-13), cell-to-cell signaling (p-value 8.74E-07),
immune cell trafficking (p-Value 3.11E-06) and infectious diseases (p-Value 9.54E-14).
Ghiabi et al. Journal of Translational Medicine  (2015) 13:27 Page 8 of 19show expression of mesenchymal markers are here re-
ferred to as “ECsMes” and ECs with no exposure to BCCs
are called “ECsNorm”.
Gene expression analysis by qPCR also demonstrated
mesenchymal and endothelial phenotypes in ECsMes by
increased expression of α-SMA and vimentin with stable
expression of endothelial VE-Cadherin and CD31 mar-
kers (Figure 2C & Additional file 1: Figure S2B). We also
checked if tumor-stimulated mesenchymal transition
in ECs was contact-dependent by growing ECs in
MDA-231 cells conditioned media (CM). We did not
detect any changes in the expression of mesenchymal
markers in ECs by flow cytometry (Additional file 1:
Figure S3A-B).
Additionally, whole transcriptomics analysis was per-
formed on ECsMes and ECsNorm. The results showed dif-
ferential expression of over 1000 genes in ECsMes as
presented in Figure 2D (left panel) (for a list of most sig-
nificantly modified genes refer to Additional file 2: S4).
IPA analysis revealed several functional pathways that
were significantly up-regulated, and among these we
identified several pathways compatible with a mesenchy-
mal phenotypes such as cell growth and proliferation (p-
Value 4.86E-29, 272 modified genes), cell movement (p-
Value 6.69E-19, 164 modified genes), cell migration (p-
Value 7.91E-19, 152 modified genes), vascular system
development (p-Value 8.30E-13, 90 modified genes),
blood vessel development (p-Value 3.97E-11, 72 modi-
fied genes), cell viability (p-Value 4.96E-15, 114 modified
genes), and cell survival (p-Value 2.13E-16, 119 modified
genes) (Figure 2D, right panel and Table 1).
Altogether, our results showed that direct contact be-
tween BCCs and ECs promotes a mesenchymal shift in
ECsMes. While there is a mesenchymal transition in
ECsMes, their endothelial trait remains unchanged. This
finding suggests that direct contact between ECs and
tumor cells in specific areas of tumor microenvironment
might create a distinct population of ECs with mesen-
chymal properties.Functional properties of ECsMes
We hypothesized that the appearance of mesenchymal
phenotype in ECsMes might instigate functional advan-
tages. To test this hypothesis, we obtained ECsMes by co-
cultivating ECs with MDA-231 or MCF-7 followed by
sorting and subsequently evaluated their functional
properties (Figure 3A & Additional file 1: Figure S5).
Since an invasive endothelium was previously implicated
in tumor development and metastasis [26], we compared
the migration/invasion property of ECsMes with ECsNorm
by performing a wound healing assay. The results
showed that ECsMes acquired an increased migration/in-
vasion property (Figure 3B, left) as they closed the
wound around three-fold faster than ECsNorm (Figure 3B,
right). It should be noted that the wound healing assay
was performed over 48 hours and under complete
starvation; therefore, wound closure was mainly the out-
come of cell migration and the possibility of cell prolifer-
ation was excluded due to lack of serum and cytokines.
To measure ECMes angiogenic potency in comparison to
ECsNorm, a conventional tube forming assay was per-
formed (Figure 3C, left). The results demonstrated
three-fold increase in the capacity of ECsMes to form
tubular branches on matrigel compared to their normal
counterparts (Figure 3C, right). Since EC proliferation
ensures angiogenesis and vasculogenesis [27,28], a pro-
liferation assay was initiated to compare the self-renewal
and survival capacity of ECsMes compared to ECsNorm.
The results demonstrated significant improvement in sur-
vival but not proliferation rate of ECsMes (Figure 3D).
Without BCCs, ECsNorm survival rate was about two-fold
lower on Day 7 (Figure 3D, right).
Finally, as has been recently shown by our group, EC
activation triggers an angiocrine switch to allow secre-
tion of angiocrine factors and cytokines that are primor-
dial for tumor growth and tissue regeneration [7]. In our
study, the sphere forming assay for constitution of
angiospheres was used as a surrogate approach for
enriching ECs with activated angiocrine phenotype.
Table 1 Transcriptomics analysis of ECsMes by Ingenuity Pathway Analysis (IPA) revealed differential expression of over
one thousand genes compared to ECsNorm
Gene name Abbreviation Fold change Functional specification (IPA or GeneCards)
Cell crowth & proliferation
Epiregulin EREG +40.266 Cell proliferation and/or angiogenesis
Amphiregulin AREG/AREGB +19.911 Growth factor & mitogen
Baculoviral IAP BIRC3 +6.765 Regulator of cell proliferation
Repeat containing 3
Budding Un- inhibited
By Benzimidazoles 1 BUB1 +6.160 Cell cycle regulator
NIMA-related kinase 2 NEK2 +5.968 Cell cycle regulator
Topoisomerase Iiα TOP Iiα +6.837 Regulator of mitosis
S100 calcium binding PS100P +6.466 Cell proliferation stimulator
Protein
Vascular growth VEGFC +2.266 Endothelial cell proliferation
Factor C
Human homolog of MDM2 +2.515 Downstream effector of Akt signaling & enhancer of
Mouse double minute 2 endothelial cell survival
Baculoviral IAP Repeat BIRC5 +3.308 Dual role in promoting proliferation & inhibiting apoptosis
Containing 5
Insulin-like growth IGFBP1 +13.116 Prolongs the half life of IGFs in cell growth promotion
Factor Binding Protein 1
Cell motility
S100 calcium binding S100A4 +2.538 Cell motility & invasion
Protein A4
Insulin-like growth IGFBP1 +13.116 Cell migration
Factor Binding Protein 1
Transforming growth TGFBI +2.934 Induced by TGFβ; has a role in inhibition of cell
Factor beta-induced adhesion
Tetraspanin 8 TSPAN8 +2.461 Regulation of cell motility
Interleukin 6 IL6 +2.214 Induction of endothelial cell motility
Krupple-like Factor 5 KLF5 +3.685 Involvement in cell movement
Heparanase HPSE +2.501 Increase endothelial cell migration
Lectin galacroside-Binding LGALS3 +2.397 Increase Endothelial cell migration
Soluble 3
Vascular development & angiogenesis
Jagged1 JAG1 +2.311 Cardiovascular development & angiogenesis
Interleukin 6 IL6 +2.214 Angiocrine factor
Vascular growth factor C VEGFC +2.266 Angiogenesis
Chemokine (C-X-C Motif) CXCR4 +5.234 Regulator of vascular branching &
Receptor 4 endothelial processes remodeling
Heparanase HPSE +2.501 Increase endothelial cell migration
RUN-related Transcription RUNX2 +6.952 Increase angiogenesis in endothelial cells
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Table 1 Transcriptomics analysis of ECsMes by Ingenuity Pathway Analysis (IPA) revealed differential expression of over
one thousand genes compared to ECsNorm (Continued)
Factor 2
Hairy/Enhancer of HEY1 +2.644 possible role in vascular development
Split-related 1
IPA functional clustering of the modified genes showed pathways activation compatible with a mesenchymal phenotype, including cell proliferation, cell motility
and angiogenesis. Some genes in each functional category are shown in this table. For a complete list of genes, refer to Additional file 2: S4.
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reported as one of several methods used to culture endo-
thelial progenitor cells with neovascularization properties
[29]. Hence, we benefitted from the sphere forming assay
and cultured ECsMes under anchorage-independent condi-
tion for 3–5 days and compared their angiosphere
(colony) forming capacity with ECsNorm. Consistent with
our previous data, we showed that ECsMes displayed
greater ability to form angiospheres as compared with
ECsNorm (Figure 3E). Collectively, our results confirmed a
significant increase in cell plasticity toward acquisition of
mesenchymal properties in ECsMes as shown by their en-
hanced migratory, angiogenic, angiocrine and survival
properties under serum- and cytokine-free conditions.
To investigate the durability of the mesenchymal trait
in ECsMes and to examine the importance of tumor con-
text for its maintenance, we continued to grow and pas-
sage ECsMes for 10–15 days under normal conditions
after sorting them from BCCs (Additional file 1: Figure
S6A). ECsNorm were cultured in parallel throughout the
experiment to serve as controls. Interestingly, the mes-
enchymal phenotype was reversed in ECsMes 15 days
after sorting from BCCs as indicated by down-regulation
of mesenchymal markers by confocal imaging (Additional
file 1: Figure S6B). Therefore, we refer to ECs with re-
versed mesenchymal phenotype as ECsReversed. This obser-
vation was further confirmed at mRNA level by qPCR
(Additional file 1: Figure S6C). To compare the functional
properties of ECsReversed with the ECsMes, we performed a
wound healing assay that showed 1.5 to 2.4-fold decrease
in ECsReversed ability to close the wound (Additional file 1:
Figure S6D). Consistent with this observation, the re-
sult of our tube formation assay also demonstrated a
2.5-fold decrease in the number of tube junctions made
by ECsReversed as compared to ECsMes (Additional file 1:
Figure S6E).
ECsMes provide a pro-tumoral niche for tumor growth and
development
To determine a role for ECsMes in breast cancer progres-
sion, we re-exposed ECsMes to freshly prepared BCCs
and evaluated proliferation, sphere forming capacity
and invasiveness of tumor cells grown with ECsMes or
ECsNorm. The experimental procedure is illustrated in
Figure 4A. Firstly, we compared BCC growth and
survival under starvation in co-culture with ECsMes orECsNorm or alone. BCCs proliferation increased 1.5-fold,
when grown with ECsMes compared to ECsNorm (Figure 4B
& Additional file 1: Figure S7). Notably, MDA-231 cells
were capable of growth and proliferation once they were
grown with ECsMes or ECsNorm and once growing alone,
they were unable to tolerate starvation and solely demon-
strated minimal survival over 7 days. To see if the ECs role
in proliferation or survival of tumor cells is contact-
dependent, we cultured MDA-231 cells in serum/cytokine
free CM of ECsNorm or ECsMes for seven days. Our results
did not show any significant increase in the survival rate
of tumor cells grown in the CM of ECsNorm or ECsMes,
which emphasize the importance of cell-to-cell contact
between the two cell types for acquisition of functional ad-
vantages (Additional file 1: Figure S3C).
Then, we examined how ECsMes influence the enrich-
ment of mammary stem cells (mammospheres). We co-
cultivated GFP+ECsMes or GFP+ECsNorm with BCCs under
anchorage-independent conditions to expand mammary
stem cells as “mammo-angiospheres” (Figure 4C, left panel).
The results showed that ECsMes were capable of enhancing
mammosphere growth about 1.6-fold compared to ECsNorm
(Figure 4C, right). We then investigated the effect of ECsMes
on the invasiveness of BCCs. Therefore, BCCs were co-
cultivated with either ECsMes or ECsNorm and a wound
healing assay was performed after sorting BCCs from the
ECs. The results confirmed that ECsMes significantly en-
hance the migration capacity of MDA-231 cells in compari-
son with ECsNorm (Figure 4D).
Our results indicate that cancer–endothelial crosstalk
potentially modulates EC plasticity; contact with tumor
cells triggers a mesenchymal (activated) phenotype in
ECs that is reversed once the tumoral context is re-
moved. Thus, cell-to-cell contact seems to be crucial for
the initiation and maintenance of the mesenchymal state
of ECsMes and may be regarded as a novel approach for
treating cancer. However, a better understanding of the
molecular mechanism regulating this interaction seems
necessary.
Tumor-stimulated mesenchymal phenotypes in ECsMes is
regulated by synergistic Notch and TGFβ pathways
Previous works demonstrated that TGFβ or notch path-
ways regulate the EndMT phenomenon during normal
and pathological developmental processes [17,18,30-33].
To investigate the involvement of notch or TGFβ
Figure 3 (See legend on next page.)
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Figure 3 Functional Properties of ECsMes. A) Schematic representation of the experimental procedures for obtaining ECsMes. BCCs were stained
with a phycoerythrin (PE)-conjugated dye (PKH26) and co-cultured with GFP+ECsNorm (1:10 ratio) for 3–5 days under starvation. Subsequently, GFP
+ECsMes were sorted from PE+BCCs using GFP and PE fluorescence and ECsMes used for functional analyses. B) Wound healing assay to assess the
migratory capacity of ECsMes as represented by their ability to close the wound (left panels). ECsMes were obtained by growing ECsNorm with either
MDA-231 (+MDA-231) or MCF-7 cells (+MCF-7). After sorting ECsMes, a 48-hour wound healing assay was initiated under complete starvation to
exclude the possibility of cell proliferation. ECsMes invasion property increased between 1.8 to 2.6-fold (right panel) compared to ECsNorm. C) Tube
formation assay for comparing the angiogenic property of ECsMes with ECsNorm (left panels). The assay was performed by growing ECsMes sorted
from either MDA-231 (+MDA-231) or MCF-7 (+MCF-7) BCCs on matrigel overnight and estimating the number of capillary-like junctions. Quantitation
of the junctions in ECsNorm versus ECsMes demonstrated three-fold increase in angiogenic capacity of ECsMes (right panel). D) Cell proliferation assay and
phase contrast imaging for evaluating survival capacity of ECsMes. ECsNorm were initially grown with MDA-231 or MCF-7 for five days to obtain ECsMes.
Then, BCCs and ECsMes were continued to grow together under starvation and their survival rate was compared to ECsNorm grown without BCCs.
Quantitative analysis estimated around two-fold increase in endurance capacity of ECsMes compared to ECsNorm (right panel). E) An Angiosphere assay was
used for evaluating the angiocrine property of ECsMes. ECsNorm or ECsMes were cultured under ultralow attachment condition to obtain angiospheres. A
two-fold increase in angiosphere numbers was observed in ECsMes compared to ECsNorm. (*** p< 0.001, **p< 0.01, mean ± SEM, n = 3).
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ECsMes, we first examined whether notch and/or TGFβ
downstream effector molecules are activated in ECsMes
compared to ECsNorm. Our qPCR results demonstrated
the up-regulation of notch downstream transcription fac-
tors Hey-1 and Hes-1 in ECsMes (Figure 5A). Concor-
dantly, our transcriptomics results confirmed the up-
regulation of several genes involved in EMT or EndMT
processes in ECsMes, among which a notch receptor as
well as signaling effectors like Hey-1 and Hes-4 were listed
(Table 2).
Earlier studies pointed out the involvement of distinct
cellular receptors, TGFβ/ALK1 (BMPs) triggering Smad1/
5/8 phosphorylation and TGFβ/ALK5 (activin) stimulating
Smad2/3 phosphorylation in endothelial transformation
[34]. Our western analysis ruled out the activation of
smad3 signaling in ECsMes (Figure 5B). However, our
results determined the activation of Smad5 in ECsMes
(Figure 5C, top lane). Also, transcriptomics data con-
firmed the up-regulation of BMPR1A receptor in ECsMes,
which was previously shown to mediate BMP-2 and BMP-
4 effect in Smad signaling activation (Table 2) [34,35].
To confirm a role for endothelial notch and TGFβ in
phosphorylation of Smad5 in ECsMes, ECsNorm were
treated with soluble forms of human recombinant Jag1
(4 μg/mL) and TGFβ1 ligands (5 ng/mL). Our western
analysis showed Smad5 phosphorylation only in re-
sponse to treating ECsNorm with Jag1 and TGFβ ligands
as was compared with total Smad5 protein (Figure 5C,
top lane). To further verify the synergistic role of Jag1/
notch and TGFβ/Smad5 in this process, we treated
ECsNorm with both Jag1 and TGFβ ligands and observed
increased level of Smad5 phosphorylation (Figure 5C,
top lane) confirming the synergistic role for the ligands
in activation of Smad5. To further validate a role for
notch pathway in this process, we showed up-regulation
of notch pathway downstream effector Hes-1 in response
to treating ECsNorm with Jag1 and/or TGFβ ligands
(Figure 5C, third lane). Band densitometry analysesshowed the highest level of Smad5 and Hes-1 activation
once ECsNorm were treated with both ligands simultan-
eously (Additional file 1: Figure S8-A).
Additionally, we treated co-cultures of ECsNorm and
MDA-231 cells with inhibitors of notch (GSI, 5 μM) and
TGFβ (SB-431542, 10 μM) pathways. After sorting ECs,
phosphorylation of Smad5 was compared with ECsMes
by western blotting. The results demonstrated that notch
and TGFβ inhibition reduced Smad5 phosphorylation
(Figure 5D, left panel). Additionally, we showed that in-
hibition of notch and TGFβ pathways down-regulated
Hes-1 protein (Figure 5D, right panel). Band densitom-
etry analysis confirmed the highest p-Smad5 and Hes-1
inhibition once ECsMes were concurrently treated with
the inhibitors (Additional file 1: Figure S8B). Besides,
our results indicated that mesenchymal phenotype in
ECsMes were down-regulated when they were treated
with GSI and SB (Additional file 1: Figure S8C). Collect-
ively, our findings suggest a synergistic role for endothe-
lial Jag1 and TGFβ in regulating tumor-stimulated
mesenchymal phenotypes in ECsMes.
To further validate our results, we established a stable
population of MDA-231Jag1-KD by using shRNA against
Jagged1 on tumor cells and determined Jagged1 down-
regulation compared to MDA-231Scrambled by qPCR
(Additional file 1: Figure S8D). Then, down-regulation of
notch downstream effectors such as Hey-1 and Hes-1
was compared between ECs that were exposed and
sorted from MDA-231Scrambled or MDA-231Jag1-KD
(Additional file 1: Figure S8E). Next, the endothelial
and mesenchymal phenotype of ECs co-cultured with
MDA-231Jag1-KD was compared to ECsMes that were
grown with MDA-231Scrambled. The confocal results con-
firmed stable expression of endothelial and mesenchymal
markers such as VE-Cadherin, CD31 in ECs grown with
MDA-231Jag1-KD (Figure 5E, top). However, mesenchymal
markers such as FN1 and F-actin were not up-regulated in
those cells (Figure 5E, bottom). These results were further
validated by qPCR analysis (Figure 5F). Moreover, in order
Figure 4 (See legend on next page.)
Ghiabi et al. Journal of Translational Medicine  (2015) 13:27 Page 13 of 19
(See figure on previous page.)
Figure 4 ECsMes provide a pro-tumoral niche for tumor growth and development. A) Schematic representation of the experimental
procedures carried out for evaluating the role of ECsMes in tumor development. ECsMes were acquired following the steps described in Figure 3A.
Next, ECsMes and ECsNorm were co-cultured with BCCs to compare their effects on cancer cell survival, cancer stem cell enrichment and cancer cell
invasiveness. B) Cell proliferation assay and phase contrast imaging showing survival or proliferation of MDA-231 cancer cells when cultured alone
or co-cultured with ECsMes or ECsNorm. Once MDA-231 cells were cultured alone under complete starvation, not only didn't they proliferate, they
minimally survived the culture condition. However, once grown with ECs, they showed significantly higher proliferation rate. ECsMes were capable
of increasing MDA-231 cell proliferation around 1.5-fold higher than ECsNorm. C) Mammosphere assay used for enriching cancer stem cells. MDA-231
cells were co-cultivated with either ECsNorm or ECsMes under anchorage-independent condition for five days and their mammosphere-enriching capacity
was evaluated by considering the number and size of the mammospheres grown in combination with ECsNorm or ECsMes. Angiospheres were
excluded from quantification by their GFP signal. Around 1.6-fold increase was observed in the rate of mammosphere (white arrowhead)
formation when they mingled with ECsMes (black arrowhead). D) Wound healing assay performed to assess the migratory capacity of breast
tumor cells when grown and sorted from ECsMes or ECsNorm. BCCs exposed and sorted from ECsNorm (ECsNorm-exposed) or ECsMes (ECsMes-exposed)
were used in a 48-hour wound healing assay under complete starvation to exclude the possibility of cell proliferation. BCCs that were grown and sorted
from ECsMes were capable of closing the wound around 1.5-fold more efficiently than those sorted from ECNorm. (*** p< 0.001, mean ± SEM, n = 3).
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MDA-231Jag1-KD (ECs St. MDAJag1-KD) compared to
ECsMes (ECs St. MDA-231Scrambled), a wound-healing assay
was performed. We observed a reduction in ECs ability
to close the gap when grown and sorted from MDA-
231Jag1-KD (Figure 5G). Overall, these findings confirm the
involvement of notch pathway in regulation of tumor-
promoted mesenchymal transitions in ECsMes.
Discussion
Our main finding is that the tumor cells promote the ac-
quisition of a transient contact-dependent mesenchymal
phenotype in ECs contributing to the generation of a
pro-tumoral niche. Transforming growth factorβ (TGFβ)
and notch pathways seem to be determinant inducers of
tumor-fostered mesenchymal phenotype in ECs.
The tumor microenvironment is implicated in the
propagation and metastasis of several tumor types
[36-38]. The role of endothelial cells (ECs) -as one the
components of tumor stroma- in cancer development
were merely thought to involve angiogenesis [26]. Re-
cently, our team demonstrated a novel role for tumor
endothelium in tissue repair, self-renewal of HSCs as
well as tumor growth and stemness by angiocrine factors
[7,8,11,13]. In addition, ECs were previously described as
cells that demonstrated a high degree of plasticity under
different conditions, a feature that is implicated in tumor
development [1,6]. Tumor-associated endothelial plasti-
city may be explained in the context of spatiotemporal
plasticity (i.e., to change phenotype and function) and
reciprocity (i.e., by processing signals received from the
environment) that have been earlier explained by Bis-
sell’s group to be fundamental in step-wise changes in
both tumor cells and their microenvironment [39-41].
Accordingly, plasticity and reciprocity account for the
morphologic and functional heterogeneity driven by
mechanisms such as cell-to-cell signaling to allow cells
to cope with altering environmental conditions [42-44].
These mechanisms might be modulated by tumor andstromal cells crosstalk to co-evolve in a dynamic micro-
environment [44,45]. Hence, our work emphasizes a
crosstalk mechanism that is absolutely dependent on
cell-to-cell contact between tumor and endothelium.
The focal points of interaction between tumor and vas-
culature might not be abundantly present within the
tumor bulk, but may potentially serve as miniature sites
within the tumor microenvironment that may enhance
neovascularization leading to increased tumor growth and
metastasis.
In this study, we demonstrated that tumor cells are
capable of promoting mesenchymal phenotype in their
neighboring endothelium. In return, the ECsMes signifi-
cantly contributed to tumor development. Although we
initially observed this phenomenon in HUVECs, we con-
tinued our work with the widely used E4-ECs [21] to cir-
cumvent the hurdle of tumor-induced HUVEC apoptosis
in co-cultures that was also reported previously by
Kebers et al. [19]. The mesenchymal transformation in
tumor endothelium in conjunction with loss of endothe-
lial phenotype has been previously described in EndMT
phenomenon as a mechanism for generation of CAFs
[17,18]. However, the acquisition of mesenchymal pheno-
type with maintenance of endothelial trait and its signifi-
cance for tumor propagation has never been explained
earlier. The importance of this phenomenon may be ex-
plained by enhanced survival, mobility and angiocrine
properties as well as the angiogenic ability of ECsMes. Our
transcriptomics data further validate our hypothesis by
showing up-regulation of pathways involved in cell devel-
opment, signaling, and movement in addition to vascular
system expansion and blood vessel formation.
The present work also focused on looking into the role
of mesenchymal endothelium (ECsMes) in breast tumor
progression. In vivo, human xenograft tumor formation
was enhanced by co-injection of ECs and tumor cells
in NOD/SCID mice showing the up-regulation of mes-
enchymal markers in tumor-associated ECs. Also, by
developing adherent (2D) and non-adherent (3D) co-
Figure 5 (See legend on next page.)
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Figure 5 Mesenchymal phenotypes in ECsMes is regulated by synergistic Notch and TGFβ pathways. A) Semi-quantitative qPCR showing
the over-expression of notch transcription factors in sorted ECsMes. (*** p < 0.001, ** p < 0.01, mean ± SEM, n = 3). B) Western analysis showing
stable p-Smad3 expression in ECsNorm and ECsMes compared to total protein. C) Western analysis demonstrating the activation of Smad5 in ECsMes
compared to ECsNorm (top lane). Once ECsNorm were treated with Jag1 and/or TGFβ1, p-Smad5 was up-regulated (top lane). Hes-1 up-regulation
in response to TGFβ1 or Jag1 treatments suggests notch pathway involvement (third lane). Simultaneous supplementation of ligands triggered
dramatic Hes-1 up-regulation in ECsNorm implying a synergistic effect. D) Western analysis displaying p-Smad1/5 down-regulation in response to notch
and/or TGFβ inhibition. GSI and SB were added to ECsNorm-MDA-231 co-cultures, then ECs were sorted for analyzing p-Smad1/5 down-regulation
comparing to total protein (left panel). Inhibition also down-regulated Hes-1 activation (right panel). Concurrent inhibitions of ECsMes dramatically
reduced p-Smad1/5 and Hes-1 activation. E) Confocal images demonstrate endothelial and mesenchymal states of ECs co-cultured with MDA-231Jag1-KD
or MDA-231Scrambled. ECs grown with MDA-231Jag1-KD demonstrated normal endothelial feature (Upper panels). However, they displayed decreased
mesenchymal phenotype compared to ECsMes (sorted from MdA-231Scrambled) (bottom panel). Scales are 10 μm. F) Semi-quantitative qPCR compared
expression of endothelial and mesenchymal markers in ECsMes and ECs sorted from MDA-231Jag1-KD cells. Silencing Jag1 and notch down-regulation in
MDA-231Jag1-KD counteracted the acquisition of mesenchymal phenotype by ECs. G) Wound healing assay to assess the migratory capacity of ECs sorted
from MDA-231Jag1-KD (ECs St. MDA-231Jag1-KD) and ECMes (sorted from MDA-231Scrambled) (left panels). After sorting, a 48-hour wound healing assay was
initiated under complete starvation to exclude the possibility of cell proliferation. The invasion property of ECs St. MDA-231Jag1-KD decreased by 1.6-fold
compared to ECsMes (right panel).
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stemness and invasiveness was evaluated. Based on a study
by Maffini et al., the preliminary target for a carcinogen is
tumor stroma and mutations in mammary epithelial cells
are not sufficient for tumor initiation [46]. Campbell’s
group earlier demonstrated that a modified stroma prefer-
entially promotes the outgrowth of abnormal epithelial
cells [44,47]. Also, a study conducted by Moses and col-
leagues demonstrated that cell signaling abnormalities in
stromal fibroblasts promoted mammary tumorigenesis in
a non-cell-autonomous manner [48,49]. Therefore, it is
primordial to study tumor microenvironmental changes
that occur during cancer progression. In addition to influ-
encing tumor initiation and progression, these changes
significantly impact the efficacy of cancer therapy specific-
ally when targeting stroma-regulated pathways [50]. In ac-
cordance with these reports, our work highlighted theTable 2 Transcriptomics analysis by IPA showed the up-
regulation of several genes in ECsMes that are involved in
EMT/EndMT processes some of which are listed in the table





Mesenchymal marker +2.54 [1,17,18]
Jagged1 Notch signaling ligand +2.31 [32-34]
Notch2 Jagged1 receptor +2.12 [32-34]
HEY1 Notch effector +2.64 [62,63]
HES4 Notch effector +2.1 [62,63]
TGFBI Involvement in EMT +2.93 [18,30,31,34]
BMPR1A TGFβ/Smad receptor +2.80 [34,35]
EGFR EMT inducer +3.78 [64,65]
WNT5B EMT inducer +2.23 [66-68]
HMGA2 EMT-inducing transcribtion factor +2.13 [69-71]
IGFBP2 EMT-inducing signaling +13.12 [72,73]
STAT2 EMT-inducing signaling +3.1 [72,74]importance of tumor contexture in fostering phenotypic
changes in ECsMes and how this alteration impact tumor
proliferation, survival, stemness and pro-metastatic prop-
erties. Therefore, elucidation of the mechanisms under-
lying microenvironment alteration will be beneficial in
targeting stroma to combat cancer.
TGFβ was previously suggested as an important role
player in the EndMT process during normal and patho-
logical situations [30,51,52]. In addition, notch signaling
was shown to promote EndMT during both cardiac de-
velopment and oncogenic transformation [32,33]. In this
study, we showed a similar phenomenon through which
tumor cells enhanced mesenchymal phenotypes in ECs
while preserving the endothelial phenotypes. We showed
that the tumor-stimulated processes leading to cre-
ation of ECMes are also mediated by phosphorylation
of TGFβ/Smad1/5 in synergy with notch pathway acti-
vation. Notch involvement in the regulation of TGFβ
signaling in ECs was previously reported [32,34,53,54].
Both synergy and antagonism between notch and
TGFβ signaling were described in ECs in a context-
dependent manner [34,53-59]. Our data confirmed
that tumor-activated TGFβ/Smad1/5 phosphorylation
was regulated by synergistic activation of notch and
TGFβ pathway by showing that TGFβ and Jag1 were
capable of inducing Smad5 phosphorylation as well as
Hes1 up-regulation. Simultaneous inhibition of notch
and TGFβ pathways not only impaired Smad5 phos-
phorylation but also impaired the acquisition of mes-
enchymal traits by ECs.
Earlier reports by Karsan’s group emphasized the im-
portance of Smad1/5 phosphorylation in promoting prolif-
eration and migration of ECs [34]. Also, phosphorylation
of Smad1/5/8 was implicated in ECs migration [60].
Consistent with these observations, we demonstrated that
tumor interaction with ECs stimulated TGFβ/Smad1/5
phosphorylation possibly resulting in gain of functional
advantages by ECsMes. Since the acquired mesenchymal
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targeted inhibition of the molecular modulators of this
process may therefore be considered as potential thera-
peutic approaches.
Our findings of the tumor-promoted mesenchymal
phenotype in ECsMes might partly explain the molecular
mechanisms that govern ECs plasticity. Interestingly, our
transcriptomics data while confirming mesenchymal
traits, demonstrated modifications of over 1000 genes
that might be relevant to tumor endothelial biology and
play roles in phenomena such as resistance to treatment
and metastasis. As such, up-regulation of previously de-
scribed angiocrine factors such as IL6, Jag1, and CXCR4
[61] in ECsMes may have potentially participated in the
constitution of a pro-tumoral niche; however, the exact
determinants of the angiocrine niche need to be clarified
in future studies. While in our settings a change to
ECsMes found to be transient, its permanence has not
yet been carefully addressed in any study. However,
the constitution of a transient niche might offer a
window for the constitution of residual or resistant
disease. Additional investigations involving in vivo ap-
proach are required to validate our data in order to
design new drugs for impairing tumor-EC interaction
as a mean to treat cancer.
Conclusion
Although the importance of microenvironment modifi-
cation in tumor development is already known, the mo-
lecular changes underlying these alterations is not well
recognized. ECs are essential components of microenvir-
onment, which influence tumor progression by establish-
ing the tumor vascular niche and producing angiocrine
factors. In addition, ECs seem to adapt to the context they
reside in by showing plasticity. This study demonstrated
that in tumor microenvironment, ECs are instructed
through tumor-derived inducers to proceed to an activa-
tion state characterized by up-regulation of mesenchymal
phenotypes. Since this interaction strongly relies on cell-
to-cell contact between tumor cell and endothelium, it
may not be widely detectable in tumor microenvironment.
Where the cell interaction occurs, the new mesenchymal
trait along with the intrinsic endothelial properties may
allow ECsMes to create a pro-tumoral niche supporting
tumor progression and metastasis. Since ECMes mesenchy-
mal characteristic is transient and strongly dependent on
tumor contexture, it may introduce a new therapeutic tar-
get for treating cancer.
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